cyrilzakka/clinical-trials huggingface dataset:
Effect of Use Smartphone in Forward Head Position and Neutral Position on Upper Limbs Nerves

To compare between two different positions (forward head position and neutral position) when using mobile phone by hand using nerve conduction velocity and F-wave of upper limb nerves ( ulnar, median and radial) in 4 different times.

PURPOSE:

* To compare between forward head position and hand use of mobile phone on conduction velocity of upper limb nerves
* To investigate the F responses of upper limbs nerves.
* To investigate the compound muscle action potential (CMAP) amplitudes of median nerves

BACKGROUND:

Forward head position may affect the cervical nerve root so it can also affect nerve conduction velocity due to continues stretch on nerves, also the over use of smart phone by hand may be affected the hand nerves, so this study determine which one of them has more influence than the other.

If the forward head position has the worst effect on the upper limb nerves investigators must avoid the incorrect position of the head to avoid stretch and compression of the nerves.

HYPOTHESES:

There are no statistical difference between forward head position and hand use of mobile phone on conduction velocity of the nerves of upper limb.

SUBJECTS:

Normal one hundred fifty non-athketic adolescents of both genders will participate in this study. Their age ranges from 14-18 years.

METHODS FOR ASSESSMENT

1. Electromyography (EMG) will be used to measure nerve conduction velocity, F-wave, motor action potential
2. Soft collar will used to fixed the craniovertebral angle during used mobile phone Universal goniometer
3. Goniometer pro iPhone application

Eligibility Criteria:
Inclusion Criteria:

1. Their ages range from 14-18 years.
2. Not rolled on any regular athletic activity

Exclusion Criteria:

1. Individual with neck pain
2. Congenital deformity for upper limb
3. Peripheral neuropathy due to diabetes mellitus type I
4. Rheumatoid arthritis
5. History of surgical intervention at nerves of the upper extremity
The Association Between Watching Mukbang Videos and the Appetite of Children With Cancer

The purpose of this study is to record the "Mukbang" watching behavior and appetite of children with cancer during inpatient radiotherapy and chemotherapy through intensive longitudinal study, explore their correlation, and the impact on their nutritional status and quality of life, and formulate for clinical departments relevant interventions and management options provide a theoretical basis.

World Health Organization（WHO） data shows that the prevalence of malnutrition in children with cancer is as high as 75%, which leads to decreased immune function in children with cancer, unsatisfactory treatment effect, increased adverse clinical outcomes, early tumor recurrence, prolonged recovery time, and death. risk factors such as increased rates. The "Global Childhood Oncology Initiative" proposed by WHO in 2020 pointed out that reducing hunger and malnutrition and improving the outcomes of children with cancer are one of the main tasks of providing best practices in pediatric oncology care.

The excessive consumption of the body caused by the cachexia of the tumor itself cannot be changed. Nutritional intake is the only adjustable factor for malnutrition in children with tumors. Loss of appetite is the main reason for insufficient nutritional intake. Numerous clinical studies have explored the nutritional management of children with cancer. However, most nutritional interventions are ineffective due to poor appetite and food intake in children.

The investigation in the clinical ward found that in order to cope with the problem of loss of appetite, many children with cancer took the initiative to watch "Mukbang" during hospitalization to relieve gastrointestinal symptoms and increase appetite. At present, studies have shown that "Mukbang" may have the potential to improve the appetite of children with tumors. In addition, watching "Mukbang" is a way that children actively choose to increase their appetite, which has better acceptability.

Intensive longitudinal study can explain the dynamic changes of children's behavior and appetite when watching "Mukbang" videos by sampling in a natural context for a short period of time and multiple times, and based on real-time data, further Explain in detail the persistent effect of watching "Mukbang" video behaviors on appetite.

Eligibility Criteria:
Inclusion Criteria:

* Aged 3-18；
* Children who conform to the Notice on Printing and Distributing the Diagnosis and Treatment Specifications for 12 Diseases Related to Hematological Diseases and Malignancies in Children (2021 Edition) issued by the General Office of the National Health and Health Commission;
* Experienced at least one complete cycle of chemotherapy and radiotherapy.

Exclusion Criteria:

* Children with severe cardiopulmonary disease, severe infection, severe organ damage, genetic metabolic disease, immunodeficiency disease or mental illness;
* Children with eye and ear dysfunction at the same time, resulting in the inability to watch and listen to videos.
A Randomized Control Study of Anti-Adhesion Agent After Colorectal Surgery

This project is to evaluate the difference of post-operation adhesion severity and adhesion area of patient received 4DryField after colorectal surgery.

This proposal will investigate the effect of the newly anti-adhesive agent 4DryField. Stoma creation is common in complicated colorectal disease. Hartman procedure (End colostomy) is used in patients advanced rectal cancer or severe diverticulitis. Loop colostomy or ileostomy is used in patients need stool diversion for prevent leakage related infection.

4DryField is a powder consisting of sterile hydrophilic microparticles, which is anufactured from highly purified potato starch in a complex process. A unique starch-based medical device is 4DryField® PH (4DryField; PlantTec Medical GmbH, Germany) as it is the only product proven to provide hemostasis and prevent the formation of adhesions. In rat model, the 4DryField acheieve the significant adhesion prevention effectiveness. In gynecologic surgery, 4DryField showed effective adhesion prevention as confirmed at second look laparoscopy. The gel is easilier to applied in the uneven surface of pelvic cavity and peristomy area than other manufacture. The indication of adhesion prevention is approved by TFDA.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing colorectal resection and temporary stoma

Exclusion Criteria:

* - Pregnancy, child, psychiatric disorder, behavior disorder, and prisoner. And those patients can't follow the protocol
The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.


Eligibility Criteria:
Inclusion Criteria:

1. Subject must have one of the clinical indications before device implant in adherence with Medicare, ACC/AHA/HRS/ESC single chamber pacing guidelines including:

   * Chronic and/or permanent atrial fibrillation with 2° or 3° AV or bifascicular bundle branch block (BBB block), including slow ventricular rates (with or without medication) associated with atrial fibrillation; or
   * Normal sinus rhythm with 2° or 3° AV or BBB block and a low level of physical activity or short expected lifespan (but at least one year); or
   * Sinus bradycardia with infrequent pauses or unexplained syncope with EP findings; and
2. Subject is ≥18 years of age; and
3. Subject has a life expectancy of at least one year; and
4. Subject is not enrolled in another clinical investigation; and
5. Subject is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams; and
6. Subject has been informed of the nature of the study, agrees to its provisions and has provided a signed written informed consent, approved by the IRB/EC; and
7. Subject is not pregnant and does not plan to get pregnant during the course of the study.

Exclusion Criteria:

1. Subject has known pacemaker syndrome, has retrograde VA conduction, or suffers a drop in arterial blood pressure with the onset of ventricular pacing; or
2. Subject is allergic or hypersensitive to \< 1 mg of dexamethasone sodium phosphate (DSP);
3. Subject has a mechanical tricuspid valve prosthesis; or
4. Subject has a pre-existing endocardial pacing or defibrillation leads; or
5. Subject has current implantation of either conventional or subcutaneous implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device; or
6. Subject has an implanted vena cava filter; or
7. Subject has evidence of thrombosis in one of the veins used for access during the procedure; or
8. Subject had recent cardiovascular or peripheral vascular surgery within 30 days of enrollment; or
9. Subject has an implanted leadless cardiac pacemaker or
10. Subject is implanted with an electrically-active implantable medical device with stimulation capabilities (such as neurological or cardiac stimulators).
Polarity Action in Electrical Stimulation Transcutaneous Donors for Treatment Areas Burned Patients

To evaluate the effect of the polarity of the electric current in healing.

The objective of this study is to evaluate the effect of the polarity of the current in healing. Both will be compared to the effects of electrical stimulation of high voltage (HVES) and neuromuscular transcutaneous electrical stimulation (TENS) in the treatment of donor sites (DA) of burn patients. It is a prospective, controlled clinical, randomized, blinded. Will be assessed 60 subjects aged 18-59 years, of both sexes, underwent the surgical procedure of grafting (PCE) were randomly divided into small blocks 5:5:5 three groups: undergoing therapeutic procedure with HVES undergoing therapeutic procedure with TENS and control. Therapeutic procedures will be applied around the DA, thigh or scalp, after 24 hours of PCE until complete healing. The variables will be the healing time estimated by the removal of the dressing rayon, clinical evaluation, scar quality, the Vancouver scale; pain, the pain numerical scale evaluation (PNS); blood perfusion by thermography; quality of healing by digital imaging, quantification of areas of crusts by the software Image J; skin biomechanical aspects as firmness, the durometer being performed reassessment at the end of treatment. Data will be submitted to analysis of normality by the Shapiro-Wilk test and the effect of behavior among groups and pre- and post-intervention will be evaluated by ANOVA-two way followed by post-hoc (Bonferroni) or Friedman, with p \<0.05. Comparing groups, before a normal distribution is applied ANOVA followed by Tukey, and otherwise will be applied the Kruskal-Wallis test and post-hoc Dunn, p\<0.05.

Eligibility Criteria:
Inclusion Criteria:

* Victims of second deep degree and third degree burns, aged between 18 and 59 years
* Both sexes
* Underwent the surgical procedure of grafting (PCE) with donor area of the scalp or thigh thick standardized mean (0.20 mm).

Exclusion Criteria:

* Diabetes,
* Infectious processes
* Use of medications that alter the healing process (corticosteroids, chemotherapy, radiotherapy, among others)
* Cognitive impairment
* Agreeing not to sign the Consent Form and Clarified or that do not fit the inclusion criteria described.
Feasibility Study on LITT for Newly Diagnosed Glioblastoma

Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System in combination with standard of care radiation therapy and temozolomide for the treatment of newly diagnosed glioblastomas (GBM).


Eligibility Criteria:
Relevant Inclusion Criteria:

1. Biopsy proven supratentorial GBM that has not undergone previous surgical resection, radiation and/or chemotherapy
2. Single enhancing lesion that is \>1 cm, but \< 4 cm in cross-sectional dimension, including thalamic tumor (≤ 3 cm)
3. The patient must be ≥18 years of age
4. KPS \> 70
5. Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder. Patients with prior malignancies must be disease-free for five years.
6. Stable cardiovascular, pulmonary health status

Relevant Exclusion Criteria:

1. Seizures occurrence or the requirement of escalation (or addition) of anti-epileptic drugs
2. Symptoms due to mass effect of the tumor including high intracranial pressure, marked edema or ≥5mm midline shift significant
3. Uncontrolled cardiovascular conditions of hypertension (systolic \>180 mm Hg), angina pectoris, or cardiac dysrhythmia; or recent history of intracranial hemorrhage
4. Serious infection, immunosuppression or concurrent medical condition (chronic or acute in nature) that may prevent safe participation or ability to meet follow-up requirements
5. Pregnancy, or planning to become pregnant
6. Patients whose physical dimensions cannot be accommodated in the MRI scanner or patients with contraindications to MRI imaging such as pacemakers, non-compatible aneurysm clips, shrapnel and other internal ferromagnetic objects
7. Patients with multiple or multifocal GBM
Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications

This study is designed to determine if point-of-care washing of allogeneic Leukocyte-Reduced Red Blood Cells reduces pulmonary complications when compared to standard-of-care Leukocyte-Reduced Red Blood Cells in a cardiac surgical population.


Eligibility Criteria:
Inclusion Criteria:

* Age equal to or greater than 18 years of age.
* Scheduled to have cardiac bypass surgery at Mayo Clinic in Rochester, Minnesota or Duke University Medical Center in Durham, North Carolina
* At risk for needing at least 4 units of blood during/after surgery

Exclusion Criteria:

* Emergency surgery
* Immunoglobulin A (IgA) deficiency
* History of severe recurrent transfusion reactions
* Refusal to receive allogeneic blood products
* Refusal to provide informed consent
* Prevalent lung injury prior to randomization
* Prevalent congestive heart failure prior to randomization
* Expected hospital stay \< 48 hours
* Not anticipated to survive \> 48 hours
* Previously enrolled in this trial
* No plan for placement of a pulmonary artery catheter
* Use of home oxygen therapy
* Complex RBC antibody profiles
* Need for the use of irradiated RBCs
An Observational Study of Patients With Chronic Kidney Disease

TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).


Eligibility Criteria:
Disease Cohort

Inclusion Criteria:

* Adult\* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface

Exclusion Criteria:

* Death
* Manual removal (sponsor or site request)
* No EHR interface encounter \> 3 years

Engaged Cohort

Inclusion Criteria:

* Adult \* patients diagnosed and managed for CKD/ESKD invited to participate
* Ability to provide written informed consent

Exclusion Criteria:

* Patient expressed desire to withdraw consent to complete PROs
* Failure to complete PROs within 24 weeks of initial invitation
* Greater than 24 months lapse of survey completion after baseline surveys completed
* Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

The concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal cancer (LARC), however, this regimen may induce sorts of adverse events, and part of them even more severer. A number of pilot studies had shown high rate of complete resection after neoadjuvant chemotherapy alone, but the results did not increase the ratio of pathological complete response (pCR), which was associated with overall survival (OS). Here, the investigators adopt the three active cytotoxic agents (Fluorouracil, Oxaliplatin, Irinotecan, FOLFOXIRI) as the neoadjuvant chemotherapy regimen to replace the concurrent chemoradiation and to improve the ratio of pCR further.

This is a multicenter, phase II trial to assess the efficacy/safety of triplet regimen (FOLFOXIRI) for patients with LARC. After 4 cycles of FOLFOXIRI and 2 weeks later, the patients will be evaluated by senior radiologist, oncologist and surgeon through pelvic MRI, CT and Positron Emission Computed Tomography (PET-CT). The patients will go to surgery (TME) if the tumor response is good enough to have complete resection under the decision of MDT,otherwise, the patients will receive pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/M\^2, bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME. All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 to 75 years at diagnosis
* Diagnosis of rectal adenocarcinoma
* ECOG status: 0～1
* Clinical stage II (T3-4, N0) or stage III (T1-4, N1-2)
* Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:
* Leukocytes ≥ 4.0 x109/ L,
* Absolute neutrophil count (ANC) ≥ 2.0 x109/ L
* Platelet count ≥ 100 x109/ L,
* Hemoglobin (Hb) ≥ 9g/ dL.
* Total bilirubin ≤1.5 x the upper limit of normal (ULN).
* Alanine aminotransferase (ALT) ≤ 3 x ULN
* Aspartate aminotransferase (AST) ≤ 3 x ULN.
* Serum creatinine ≤ 1.5 x the ULN.
* Signed informed consent;

Exclusion Criteria:

* Patient had received pelvic radiotherapy
* Patient had received systemic chemotherapy
* Pregnant and Nursing women
* Had metastatic disease
* Uncontrolled co-morbid illnesses or other concurrent disease
* Patient had second malignant disease within 5 years
* Patients refused to signed informed consent.
MapMySmoke: Smoking Cessation App With Geospatial Capture

Place-based cues can be an important trigger of smoking behavior, therefore the investigators wish to learn more about the influence of the built environment on individual smoking behavior. This is to facilitate dynamic support during the post-quit phase. MapMySmoke is a mobile phone application that enables the capture of spatial data during smoking and craving events. These data will be used to create individualized support plans via the app.

Investigators know that place-based cues play an important role in the triggering of smoking events, and even in relapse events. It follows that providing individual smokers with spatially explicit and temporally dynamic intervention messages may support smoking cessation attempts.

The investigators have built a mobile phone application-MayMySmoke-that allows individuals to capture each smoking event at the times and places they occur, and tag the events with qualitative metadata. The app also allows individuals to document and describe craving events. The goal of the app is first to understand an individual's smoking profile, and second to support them with dynamic text messages.

The investigators are deploying the app in a clinical setting-the United Kingdom's National Health Service, within the Fife region of Scotland. Using two feasibility studies of increasing size, the investigators are attempting first to get initial feedback on the app, and then to improve the app and deploy it across a broader community of smokers.

Though the app is targeted to smoking behavior, it is possible to extend it to include other negative health behaviors that may have a spatial component.

Eligibility Criteria:
Inclusion Criteria:

* National Health Service (Fife) Patients
* Self-reported tobacco smoker
* Stated intention to quit smoking
* English speaker

Exclusion Criteria:

* Mental illness
* learning difficulty
NMR Metabolomics Study of Follicular Fluid of Oncological Patients

Purpose: The purpose of this study was to evaluate the possible application of metabolomics to identify follicular fluid changes in cancer patients undergoing fertility preservation. Although metabolomics have been applied already in cancer studies, this is the first application on follicular fluid of cancer patients.

Methods: The investigators selected for the study 10 patients with breast cancer and lymphoma who resorted to oocyte cryopreservation to preserve fertility and 10 healthy women undergoing in vitro fertilization treatments. Follicular fluid was collected at the time of oocytes retrieval. Metabolomic analysis of follicular fluids was performed by 1H NMR spectroscopy in combination with multivariate analysis to interpret the spectral data. Univariate statistical analysis was applied to find correlations between patients' features and metabolites identified by NMR.

The purpose of this study was to evaluate the possible application of metabolomics to identify follicular fluid changes in cancer patients undergoing fertility preservation. Although metabolomics have been applied already in cancer studies, this is the first application on follicular fluid of cancer patients.

Methods: The investigators selected for the study 10 patients with breast cancer and lymphoma who resorted to oocyte cryopreservation to preserve fertility and 10 healthy women undergoing in vitro fertilization treatments. Follicular fluid was collected at the time of oocytes retrieval. Metabolomic analysis of follicular fluids was performed by 1H NMR spectroscopy in combination with multivariate analysis to interpret the spectral data. Univariate statistical analysis was applied to find correlations between patients' features and metabolites identified by NMR.

Eligibility Criteria:
Inclusion Criteria:

* all nulliparous patients who want to have offspring, with a cancer diagnosis obtained by histological examination and with a definitive staging of the disease.

Exclusion Criteria:

* patients with suspected cancer diagnosis without histological examination and complete staging and women suffering of any cancer that received neoadjuvant chemotherapy or radiation therapy prior to follicular fluid collection.
Effect Of Abdominal Hypopressive Training On Stress Urinary Incontinence

Fifty female athletes suffering from stress incontinence (SUI) will participate in this study. They will be selected from El Zohour Club, New Cairo City.

They will be randomly distributed into 2 groups equal in numbers:

Group (A) (Control group) consists of 25 female athletes. They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.

Group (B) (Study group) consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.

Before data collection, the purpose and procedures will be fully explained to the females. Informed consent will be obtained from each female. Each female will be evaluated following a standard protocol.

Eligibility Criteria:
Inclusion Criteria:

1. Female athletes suffering from SUI.
2. They will be diagnosed with SUI using bladder stress test.
3. Their ages will range from 14-18 years old.
4. Their body mass index (BMI) will range from 18.5-24.9 kg/m2.
5. They are single females.

Exclusion Criteria:

The female athlete will be excluded if they had:

1. Urinary tract infection.
2. Family history of genito-urinary tract cancer.
3. Diabetes mellitus.